Scott Ed­mond­son leaves As­traZeneca, starts new chap­ter at Nim­bus; With IPO filed, Taysha pulls to­geth­er an AveX­is-heavy team

Nim­bus Ther­a­peu­tics, which iden­ti­fied 4 new tar­gets – AMP­Kβ2, CTPS1, Cbl-b and WRN – in their drug dis­cov­ery ef­forts, has reeled in a big fish with Big Phar­ma vet Scott Ed­mond­son now a part of the mix as SVP, head of chem­istry. Ed­mond­son had been As­traZeneca’s di­rec­tor and head of Boston on­col­o­gy chem­istry for al­most 4 years.

From 1998-2016, Ed­mond­son was at Mer­ck and worked his way up to di­rec­tor of dis­cov­ery chem­istry. While at the phar­ma gi­ant, he dis­cov­ered vibegron for pa­tients with over­ac­tive blad­der, a drug that Urovant would pick up in 2017. Urovant filed for an NDA for vibegron at the FDA, which the agency ac­cept­ed for re­view in March.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.